Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers November 19, 2018
Pharmacy Choice - News - Drug Delivery Systems - November 19, 2018

Pharmacy News

 Drug Delivery Systems
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 91     Next >>     Go To Page:

11/19/18 - FDA Approves AEMCOLO? (Rifamycin), the First Antibiotic Approved for the Treatment of Travelers Diarrhea in Over a Decade
Dublin, Ireland- November 19, 2018- Cosmo Pharmaceuticals N.V. announced that the U.S. Food and Drug Administration has approved AEMCOLO?, containing 194 mg of Rifamycin as delayed-release tablets, a new minimally-absorbed antibiotic that is delivered to the colon, for treatment of Travelers' Diarrhea caused by non-invasive strains of Escherichia
11/19/18 - Innovus Pharmaceuticals Acquires Worldwide Rights to Four Products from Boston Topicals, LLC
Innovus Pharmaceuticals, Inc.,, an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter and consumer care products to improve men s and women's health and respiratory diseases, announced today that the Company has acquired four branded topical products from Boston Topicals, LLC, expanding
11/19/18 - Pivot Naturals LLC Receives Three Additional Notices of Allowance from USPTO
-Pivot Pharmaceuticals Inc. is pleased to announce that its wholly-owned subsidiary, Pivot Naturals LLC, has received three more Notices of Allowance from the U.S. Patent and Trademark Office for patent applications related to its RTIC "Ready-To-Infuse Cannabis" powderization technology. Pivot Naturals LLC granted three additional Notices of Allowa
11/18/18 - Idrasil Could Be The First Standardized Medical Marijuana Prescription Pill
Steele Clarke Smith III is chairman and CEO of C3 International, a post-proof of concept, pre-revenue life sciences company specializing in cannabinoid therapeutics. C3's pioneering patient, a 21- year-old San Diego man, came monthly from San Diego for raw cannabis and capsules prepared for him, Smith said. As part of a wider DEA operation in South
11/17/18 - Biopharmaceutical Success Depends on Delivery, Fueling $7.8 BN Market: Report [Syrian Arab News Agency]
Market research firm Kalorama Information said that the total market for biopharmaceutical drug delivery devices is estimated at $7.8 billion, boosted by developments in implants, pumps, and microfluidics, as well as needle-free injectors. Sales of select biopharmaceuticals have been brisk: Enbrel $7.8 billion, Remicade $8.1 billion, Humira $18.6 b
11/17/18 - Do needle exchanges reduce the spread of infectious disease? The research isn't clear.
The numbers are staggering- 233 confirmed drug overdose deaths this year in Milwaukee, Wisconsin, with 188 because of opioids, according to Karen Domagalski, operations manager for the Milwaukee County medical examiner's office. In Wisconsin last year, there were 829 deaths from drug overdoses- many involving the injection of heroin and fentanyl, A
11/17/18 - FDA Approves First-line Treatment for Peripheral T-cell Lymphoma Under New Review Pilot
The U.S. Department of Health and Human Services' Food and Drug Administration issued the following news release:. The U.S. Food and Drug Administration today expanded the approved use of Adcetris injection in combination with chemotherapy for adult patients with certain types of peripheral T-cell lymphoma. "The Real-Time Oncology Review program a
11/17/18 - Glenmark gets USFDA nod for multiple sclerosis medication [Sport360]
Glenmark Pharmaceuticals, USA, has been granted final approval by the United States Food and Drug Administration for Teriflunomide tablets in the strengths of 7 mg and 14 mg, the company said in a BSE filing. Glenmark said with respect to 180- day generic drug exclusivity, it was one of the applicants to submit a substantially complete first abbrev
11/17/18 - Shilpa Medicare gets tentative USFDA nod for multiple sclerosis drug [Sport360]
Shilpa Medicare Thursday said it has received tentative approval from the US health regulator for Dimethyl Fumarate delayed release capsules, used for treatment of relapsing forms of multiple sclerosis. The company`s abbreviated new drug application for Dimethyl Fumarate delayed release capsules in the strengths of 120 mg and 240 mg has been grante
11/16/18 - Aquestive Therapeutics Receives Complete Response Letter from U.S. Food and Drug Administration (FDA) for Tadalafil Oral Film
Aquestive Therapeutics, Inc. today announced it received a complete response letter from the U.S. Food and Drug Administration in regards to its New Drug Application for tadalafil oral film. The comments provided in the CRL are manageable and we will work with the FDA to map out our path to resubmission and approval, "said Keith J. Kendall, Chief
11/16/18 - FDA approves first-line treatment for peripheral T-cell lymphoma under new review pilot
The U.S. Food and Drug Administration today expanded the approved use of Adcetris injection in combination with chemotherapy for adult patients with certain types of peripheral T-cell lymphoma. This is the first FDA approval for treatment of newly diagnosed PTCL, and the agency used a new review program to complete the approval more quickly.
11/16/18 - Global $90+ Billion Controlled Release Drug Delivery Market to 2025
The "Controlled Release Drug Delivery Market Analysis Report By Technology, By Release Mechanism, By Application, And Segment Forecasts, 2018- 2025" report has been added to ResearchAndMarkets.com' s offering. The global controlled release drug delivery market size is expected to reach USD 90.18 billion by 2025, experiencing a CAGR of 14.0% during
11/16/18 - Global Controlled Release Drug Delivery Market Analysis Report 2014-2018 & 2025 By Technology (Implants, Transdermal, Microencapsulation, Targeted Delivery), Release Mechanism, & Application
The "Controlled Release Drug Delivery Market Analysis Report By Technology, By Release Mechanism, By Application, And Segment Forecasts, 2018- 2025" report has been added to ResearchAndMarkets.com' s offering. The global controlled release drug delivery market size is expected to reach USD 90.18 billion by 2025, experiencing a CAGR of 14.0% during
11/16/18 - Global Controlled Release Drug Delivery Market Analysis Report 2014-2018 & 2025 By Technology (Implants, Transdermal, Microencapsulation, Targeted Delivery), Release Mechanism, & Application - ResearchAndMarkets.com
The "Controlled Release Drug Delivery Market Analysis Report By Technology, By Release Mechanism, By Application, And Segment Forecasts, 2018- 2025" report has been added to ResearchAndMarkets.com' s offering. The global controlled release drug delivery market size is expected to reach USD 90.18 billion by 2025, experiencing a CAGR of 14.0% during
11/16/18 - Global Sustained Release Excipients Market Analysis & Forecast Report 2015-2018 & 2026: Increasing Focus on Novel Drug Delivery R&D and Rising Adoption of Extended Release Formulations
The "Sustained Release Excipients Market Size, Share& Trends Analysis Report By Product, By Route of Administration, By Technology, And Segment Forecasts, 2018- 2026" report has been added to ResearchAndMarkets.com' s offering. The global sustained release excipients market size is expected to reach USD 1.6 billion by 2026 at a 7.1% CAGR during t
11/16/18 - Global Syringes Market Outlook to 2024: Strategic Business Report - Industry Witnesses Rapid Shift from Glass to Plastic
The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East& Africa, and Latin America. Abbott Laboratories, Inc. B. Braun Melsungen AG Becton, Dickinson and Company Cardinal Health, Inc. Gerresheimer AG Kawamoto Corporation Medline Industries, Inc. Merit Medical Systems, Inc. Nipro Medical Corp
11/16/18 - Make in Odisha: Bharat Biotech to invest Rs 500 cr for vaccine-making unitinKhurda district [New Indian Express (India)]
BHUBANESWAR: Hyderabad- based vaccine major Bharat Biotech International Ltd has committed to invest `500 crore in the State to set up a vaccine manufacturing unit in the Biotechnology Park near Khurda. Making the announcement on the last day of Make-in-Odisha Conclave 2018 on Thursday, founder of BBIL and Chairman of Odisha Biotech Park Pvt Ltd Kr
11/16/18 - Seattle Genetics Announces FDA Approval of ADCETRIS (Brentuximab Vedotin) in Combination with Chemotherapy for Adults with Previously Untreated Systemic Anaplastic Large Cell Lymphoma or Other CD30-Expressing Peripheral T-Cell Lymphomas
Seattle Genetics, Inc. today announced a new approval for ADCETRIS in combination with CHP chemotherapy from the U.S. Food and Drug Administration for adults with previously untreated systemic anaplastic large cell lymphoma or other CD30-expressing peripheral T-cell lymphomas, including angioimmunoblastic T-cell lymphoma and PTCL not otherwise..
11/16/18 - The 2018 Market for Syringes - Global Strategic Business Report Outlook to 2024, Featuring Profiles for 90 Key & Niche Market Players
The "Syringes- Global Strategic Business Report" report has been added to ResearchAndMarkets.com' s offering. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East& Africa, and Latin America. Asia- Central for Future Growth.
11/16/18 - The 2018 Market for Syringes - Global Strategic Business Report Outlook to 2024, Featuring Profiles for 90 Key & Niche Market Players - ResearchAndMarkets.com
The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East& Africa, and Latin America. Abbott Laboratories, Inc. B. Braun Melsungen AG Becton, Dickinson and Company Cardinal Health, Inc. Gerresheimer AG Kawamoto Corporation Medline Industries, Inc. Merit Medical Systems, Inc. Nipro Medical Corp
11/15/18 - Advanced Parenteral Drug Delivery Devices Market Report 2018- 2025 by Size, Share, Application and Trend : Abbott, Pfizer, AstraZeneca, Baxter, Dickinson, Boston Scientif: A closer look at the overall Advanced Parenteral Drug Delivery Devices busines
New York, NY 11/15/2018 The latest market research report on Advanced Parenteral Drug Delivery Devices market, samples and measures quality data on the overall business environment for the forecast period 2018-2025. Comprehensive data on growing investment pockets evaluated in the report on Advanced Parenteral Drug Delivery Devices market are
11/15/18 - CURE Pharmaceutical Names Veteran Executive as Chief Financial Officer [Palestine News Network]
-CURE Pharmaceutical, an innovative drug delivery and development company, today announced it has tapped Alex Katz to be the companys Chief Financial Officer. Our company is approaching 2019 amidst exponential growth and a clear vision to be a leader in drug delivery innovation, said Robert Davidson, CEO and Chairman of the Board of CURE Pharmaceut
11/15/18 - Data on Drug Delivery Systems Reported by Researchers at Qingdao University of Science and Technology (Novel ultra-small micelles based on rebaudioside A: A potential nanoplatform for ocular drug delivery)
Financial supporters for this research include National Natural Science Foundation of China, Project of Medical and Health Technology Development Program in Shandong Province, China. For more information on this research see: Novel ultra-small micelles based on rebaudioside A: A potential nanoplatform for ocular drug delivery. International Journal
11/15/18 - Data on Transdermal Delivery Detailed by Researchers at Iowa State University (The impact of pain on the pharmacokinetics of transdermal flunixin meglumine administered at the time of cautery dehorning in Holstein calves)
By a News Reporter-Staff News Editor at Biotech Week Researchers detail new data in Drugs and Therapies- Transdermal Delivery. According to news reporting originating in Ames, Iowa, by NewsRx journalists, research stated, "To study the influence of pain on the pharmacokinetics and anti-inflammatory actions of transdermal flunixin administered at.
11/15/18 - FDA Alerts Doctors, Patients About Risk of Complications When Certain Implanted Pumps are Used to Deliver Pain Medications Not Approved for Use With the Devices
The U.S. Food and Drug Administration today alerted health care providers and patients about the serious complications that can occur when using medications not approved for use with implanted pumps that deliver medication into the spinal fluid to treat or manage pain. This is especially true when it comes to implantable pumps that deliver analgesi
Articles(s): 1 - 25 of 91     Next >>     Go To Page:


© 2018 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
RxSchool
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2018 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415